Understanding Pomalyst® (pomalidomide) capsules

Pomalyst® (pomalidomide) is an immunomodulatory agent approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of adult patients with relapsed and refractory myeloma who have received at least 2 prior therapies, including Revlimid® (lenalidomide) and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalyst is an oral medication taken by mouth in capsule form.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.